manidipine

Also Known As:

(+)-manidipine; (+)-manidipine dihydrochloride; (-)-manidipine; (-)-manidipine dihydrochloride; (R)-(-)-manidipine; (R)-(-)-manidipine dihydrochloride; (R)-manidipine; (R)-manidipine dihydrochloride; (S)-(+)-manidipine; (S)-(+)-manidipine dihydrochloride; (S)-manidipine; (S)-manidipine dihydrochloride; 2-(4-diphenylmethyl-1-piperazinyl)ethyl methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate; CV 4093; CV-4093; manidipine dihydrochloride; manidipine hydrochloride; manidipine, (+-)-isomer

Networked: 130 relevant articles (20 outcomes, 45 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Fogari, Roberto: 11 articles (01/2011 - 07/2003)
2.	Mugellini, Amedeo: 9 articles (01/2011 - 07/2003)
3.	Zoppi, Annalisa: 7 articles (01/2008 - 07/2003)
4.	Rinaldi, Andrea: 5 articles (01/2008 - 07/2003)
5.	Lazzari, Pierangelo: 4 articles (01/2008 - 04/2005)
6.	Preti, Paola: 4 articles (01/2008 - 07/2003)
7.	Martinez-Martin, Francisco Javier: 3 articles (01/2018 - 11/2008)
8.	Alberici, Marco: 3 articles (01/2013 - 07/2003)
9.	Schmieder, Roland E: 3 articles (01/2013 - 04/2008)
10.	Cremonesi, Giovanni: 3 articles (01/2011 - 09/2004)

Related Diseases

1.	Hypertension (High Blood Pressure) 01/01/1996 - "In conclusion, manidipine at an individualized dose of 10 or 20 mg. was effective and safe in the management of arterial hypertension. " 01/01/1992 - "Nephroprotective actions and other tissue protective effects of manidipine in the management of hypertension." 01/01/2004 - "Thus, manidipine represents a first-line treatment option for patients with essential mild-to-moderate hypertension." 02/01/1993 - "Efficacy of manidipine in the treatment of hypertension with renal impairment: a multicenter trial." 06/01/2010 - "Our data supports the added value of manidipine in the treatment of patients with hypertension and microalbuminuria."
2.	Essential Hypertension 01/01/1996 - "Evaluation by 24-hour ambulatory blood pressure monitoring of efficacy of manidipine hydrochloride 10, 20 or 40 mg once daily as compared to placebo in treating mild to moderate essential hypertension: a double-blind, randomized, parallel group, placebo-controlled study." 01/01/1992 - "Efficacy of manidipine on circadian blood pressure in essential hypertension." 11/01/2004 - "In clinical studies, manidipine has been shown to significantly lower office and 24-h blood pressure compared with placebo in patients with essential hypertension. " 01/01/2001 - "In a well controlled short term trial, manidipine 10 mg daily significantly decreased trough sitting BP compared with placebo in elderly patients with mild to moderate essential hypertension. " 01/01/2001 - "Manidipine 10 to 40mg once daily for 4 weeks significantly lowered office BP from baseline and compared with placebo, and significantly reduced 24-hour BP compared with placebo in patients with essential hypertension in a well controlled trial. "
3.	Type 2 Diabetes Mellitus (MODY) 01/01/2004 - "Manidipine is also effective in hypertensive patients with comorbidities, such as type 2 diabetes mellitus and/or renal impairment, and appears to improve insulin sensitivity without affecting metabolic function. " 06/01/1996 - "This study confirmed the improving effects on SI and SG by long-term treatment with manidipine or delapril in the hypertensive NIDDM patients." 11/01/2011 - "Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial." 06/01/1996 - "Treatment with manidipine or delapril significantly reduced systolic and diastolic blood pressures in the hypertensive NIDDM patients. " 02/01/2005 - "This multicenter, double-blind trial compared manidipine and enalapril in patients with type 2 diabetes and hypertension (diastolic blood pressure [DBP] 90-104 mm Hg, systolic blood pressure [SBP] < or =190 mm Hg). "
4.	Stroke (Strokes) 12/01/1995 - "1. We evaluated the protective effects of manidipine on spermatogenic damage induced by the hypertensive vascular changes in stroke-prone spontaneously hypertensive rats (SHRSP). " 12/01/1995 - "Protective effects of manidipine on spermatogenesis in stroke-prone spontaneously hypertensive rats." 03/01/1997 - "Manidipine improves spermatogenesis in the stroke-prone spontaneously hypertensive rat." 11/01/1995 - "In the combination group and manidipine 2HCl-treated group, the neurological deficits after the onset of stroke were ameliorated during the entire experimentalperiod. " 02/01/1993 - "Furthermore, manidipine prevents the development of cerebrovascular lesions and inhibits the progression of vascular damage in the brain and kidneys of stroke-prone spontaneously hypertensive rats. "
5.	COVID-19 03/10/2021 - "We identified 35 drugs that reduced viral replication in Vero and human hepatocytes when treated prior to SARS-CoV-2 infection and found amodiaquine, atovaquone, bedaquiline, ebastine, LY2835219, manidipine, panobinostat, and vitamin D3 to be effective in slowing SARS-CoV-2 replication in human cells when used to treat infected cells. " 01/01/2021 - "Using the nano-luciferase as a measure of virus replication we identified 35 drugs that reduced replication in Vero cells and human hepatocytes when treated prior to SARS-CoV-2 infection and found amodiaquine, atovaquone, bedaquiline, ebastine, LY2835219, manidipine, panobinostat, and vitamin D3 to be effective in slowing SARS-CoV-2 replication in human cells when used to treat infected cells. "

Related Drugs and Biologics

1.	delapril
2.	Antihypertensive Agents (Antihypertensives)
3.	Hydrochlorothiazide (Esidrix)
4.	Enalapril
5.	Losartan (Cozaar)
6.	Irbesartan
7.	Valsartan (Vals)
8.	Atovaquone (Mepron)
9.	Ramipril (Altace)
10.	Cholecalciferol (Vitamin D3)

Related Therapies and Procedures

1.	Therapeutics
2.	Sodium-Restricted Diet (Diet, Sodium Restricted)
3.	Continuous Ambulatory Peritoneal Dialysis (CAPD)
4.	Microelectrodes
5.	Intravenous Injections